Cargando…

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines

SIMPLE SUMMARY: We used PCR-generated small CRISPR constructs to edit two genes (IDH2 and MYBL2) in hard-to-transfect hemopoietic cells, which are central to the progression of the devastating disease known as acute myeloid leukemia LMA (AML). MYBL2 is a transcription factor; when AML patients show...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Romero, Elisa, Martínez-Valiente, Cristina, García-García, Gema, Rosal-Vela, Antonio, Millán, José María, Sanz, Miguel Ángel, Sanz, Guillermo, Liquori, Alessandro, Cervera, José Vicente, Vázquez-Manrique, Rafael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487029/
https://www.ncbi.nlm.nih.gov/pubmed/37686539
http://dx.doi.org/10.3390/cancers15174263
_version_ 1785103138587410432
author González-Romero, Elisa
Martínez-Valiente, Cristina
García-García, Gema
Rosal-Vela, Antonio
Millán, José María
Sanz, Miguel Ángel
Sanz, Guillermo
Liquori, Alessandro
Cervera, José Vicente
Vázquez-Manrique, Rafael P.
author_facet González-Romero, Elisa
Martínez-Valiente, Cristina
García-García, Gema
Rosal-Vela, Antonio
Millán, José María
Sanz, Miguel Ángel
Sanz, Guillermo
Liquori, Alessandro
Cervera, José Vicente
Vázquez-Manrique, Rafael P.
author_sort González-Romero, Elisa
collection PubMed
description SIMPLE SUMMARY: We used PCR-generated small CRISPR constructs to edit two genes (IDH2 and MYBL2) in hard-to-transfect hemopoietic cells, which are central to the progression of the devastating disease known as acute myeloid leukemia LMA (AML). MYBL2 is a transcription factor; when AML patients show an altered expression of this factor, an adverse prognostic value is involved. IDH2 is particularly interesting because it encodes isocitrate dehydrogenase 2, an enzyme of the citric acid cycle, which, when mutated, produces a different phenotype in AML patients. Hence, our system provides a way to produce CRISPR constructs to easily target genes within mammalian cells, and it provides a model which can be used to study AML mechanisms in vitro. ABSTRACT: Acute myeloid leukemia is a complex heterogeneous disease characterized by the clonal expansion of undifferentiated myeloid precursors. Due to the difficulty in the transfection of blood cells, several hematological models have recently been developed with CRISPR/Cas9, using viral vectors. In this study, we developed an alternative strategy in order to generate CRISPR constructs by fusion PCR, which any lab equipped with basic equipment can implement. Our PCR-generated constructs were easily introduced into hard-to-transfect leukemic cells, and their function was dually validated with the addition of MYBL2 and IDH2 genes into HEK293 cells. We then successfully modified the MYBL2 gene and introduced the R172 mutation into the IDH2 gene within NB4 and HL60 cells that constitutively expressed the Cas9 nuclease. The efficiency of mutation introduction with our methodology was similar to that of ribonucleoprotein strategies, and no off-target events were detected. Overall, our strategy represents a valid and intuitive alternative for introducing desired mutations into hard-to-transfect leukemic cells without viral transduction.
format Online
Article
Text
id pubmed-10487029
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104870292023-09-09 PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines González-Romero, Elisa Martínez-Valiente, Cristina García-García, Gema Rosal-Vela, Antonio Millán, José María Sanz, Miguel Ángel Sanz, Guillermo Liquori, Alessandro Cervera, José Vicente Vázquez-Manrique, Rafael P. Cancers (Basel) Article SIMPLE SUMMARY: We used PCR-generated small CRISPR constructs to edit two genes (IDH2 and MYBL2) in hard-to-transfect hemopoietic cells, which are central to the progression of the devastating disease known as acute myeloid leukemia LMA (AML). MYBL2 is a transcription factor; when AML patients show an altered expression of this factor, an adverse prognostic value is involved. IDH2 is particularly interesting because it encodes isocitrate dehydrogenase 2, an enzyme of the citric acid cycle, which, when mutated, produces a different phenotype in AML patients. Hence, our system provides a way to produce CRISPR constructs to easily target genes within mammalian cells, and it provides a model which can be used to study AML mechanisms in vitro. ABSTRACT: Acute myeloid leukemia is a complex heterogeneous disease characterized by the clonal expansion of undifferentiated myeloid precursors. Due to the difficulty in the transfection of blood cells, several hematological models have recently been developed with CRISPR/Cas9, using viral vectors. In this study, we developed an alternative strategy in order to generate CRISPR constructs by fusion PCR, which any lab equipped with basic equipment can implement. Our PCR-generated constructs were easily introduced into hard-to-transfect leukemic cells, and their function was dually validated with the addition of MYBL2 and IDH2 genes into HEK293 cells. We then successfully modified the MYBL2 gene and introduced the R172 mutation into the IDH2 gene within NB4 and HL60 cells that constitutively expressed the Cas9 nuclease. The efficiency of mutation introduction with our methodology was similar to that of ribonucleoprotein strategies, and no off-target events were detected. Overall, our strategy represents a valid and intuitive alternative for introducing desired mutations into hard-to-transfect leukemic cells without viral transduction. MDPI 2023-08-25 /pmc/articles/PMC10487029/ /pubmed/37686539 http://dx.doi.org/10.3390/cancers15174263 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
González-Romero, Elisa
Martínez-Valiente, Cristina
García-García, Gema
Rosal-Vela, Antonio
Millán, José María
Sanz, Miguel Ángel
Sanz, Guillermo
Liquori, Alessandro
Cervera, José Vicente
Vázquez-Manrique, Rafael P.
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title_full PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title_fullStr PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title_full_unstemmed PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title_short PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines
title_sort pcr-based strategy for introducing crispr/cas9 machinery into hematopoietic cell lines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487029/
https://www.ncbi.nlm.nih.gov/pubmed/37686539
http://dx.doi.org/10.3390/cancers15174263
work_keys_str_mv AT gonzalezromeroelisa pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT martinezvalientecristina pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT garciagarciagema pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT rosalvelaantonio pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT millanjosemaria pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT sanzmiguelangel pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT sanzguillermo pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT liquorialessandro pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT cerverajosevicente pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines
AT vazquezmanriquerafaelp pcrbasedstrategyforintroducingcrisprcas9machineryintohematopoieticcelllines